AU2003295697B2 - Forming iron nitrosyl hemoglobin - Google Patents

Forming iron nitrosyl hemoglobin Download PDF

Info

Publication number
AU2003295697B2
AU2003295697B2 AU2003295697A AU2003295697A AU2003295697B2 AU 2003295697 B2 AU2003295697 B2 AU 2003295697B2 AU 2003295697 A AU2003295697 A AU 2003295697A AU 2003295697 A AU2003295697 A AU 2003295697A AU 2003295697 B2 AU2003295697 B2 AU 2003295697B2
Authority
AU
Australia
Prior art keywords
hemoglobin
nitrite
blood
red blood
blood cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003295697A
Other languages
English (en)
Other versions
AU2003295697A8 (en
AU2003295697A1 (en
Inventor
David J. Singel
Jonathan S. Stamler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University – Bozeman
Duke University
Original Assignee
Montana State University – Bozeman
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University – Bozeman, Duke University filed Critical Montana State University – Bozeman
Publication of AU2003295697A8 publication Critical patent/AU2003295697A8/xx
Publication of AU2003295697A1 publication Critical patent/AU2003295697A1/en
Application granted granted Critical
Publication of AU2003295697B2 publication Critical patent/AU2003295697B2/en
Priority to AU2010201151A priority Critical patent/AU2010201151B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003295697A 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin Ceased AU2003295697B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010201151A AU2010201151B2 (en) 2002-12-12 2010-03-23 Forming Iron Nitrosyl Hemoglobin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43261602P 2002-12-12 2002-12-12
US60/432,616 2002-12-12
PCT/US2003/037081 WO2004054433A2 (en) 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010201151A Division AU2010201151B2 (en) 2002-12-12 2010-03-23 Forming Iron Nitrosyl Hemoglobin

Publications (3)

Publication Number Publication Date
AU2003295697A8 AU2003295697A8 (en) 2004-07-09
AU2003295697A1 AU2003295697A1 (en) 2004-07-09
AU2003295697B2 true AU2003295697B2 (en) 2009-12-24

Family

ID=32595081

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003295697A Ceased AU2003295697B2 (en) 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin
AU2010201151A Ceased AU2010201151B2 (en) 2002-12-12 2010-03-23 Forming Iron Nitrosyl Hemoglobin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010201151A Ceased AU2010201151B2 (en) 2002-12-12 2010-03-23 Forming Iron Nitrosyl Hemoglobin

Country Status (6)

Country Link
US (1) US8075922B2 (cg-RX-API-DMAC7.html)
EP (1) EP1575419B1 (cg-RX-API-DMAC7.html)
JP (2) JP5305554B2 (cg-RX-API-DMAC7.html)
AU (2) AU2003295697B2 (cg-RX-API-DMAC7.html)
CA (1) CA2509817C (cg-RX-API-DMAC7.html)
WO (1) WO2004054433A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
EP1863503B1 (en) 2005-03-07 2019-05-22 Sangart, Inc. Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
CN1325518C (zh) * 2005-09-09 2007-07-11 李勇 人细胞膜抗原的保存方法及磁性粒子包被人细胞膜抗原
DE102007026071A1 (de) * 2007-05-24 2008-11-27 Seereal Technologies S.A. Richtungsgesteuerte Beleuchtungseinheit für ein autostereoskopisches Display
WO2009029836A2 (en) * 2007-08-31 2009-03-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
WO2009038796A1 (en) 2007-09-20 2009-03-26 Wake Forest University Health Sciences Methods of treatment for hemolysis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030006A1 (en) * 1995-03-24 1996-10-03 Brigham And Women's Hospital Nitrosylated blood substitutes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US6291424B1 (en) * 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
AT405135B (de) * 1997-01-17 1999-05-25 Immuno Ag Präparation umfassend thiolgruppen-hältige proteine
CA2278784A1 (en) 1997-02-06 1998-08-13 Jonathan S. Stamler No-modified hemoglobins and uses therefor
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
EP1204870B1 (en) * 1999-08-02 2010-01-20 Duke University Method for determining physiological effects of hemoglobin
EP1514103A4 (en) 2002-05-29 2006-05-24 Univ Duke MEASUREMENT OF NITROGEN MONOXIDE IN HEMOTOXIC GASES, AND TREATMENT BASED ON THIS MEASURE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030006A1 (en) * 1995-03-24 1996-10-03 Brigham And Women's Hospital Nitrosylated blood substitutes

Also Published As

Publication number Publication date
AU2003295697A8 (en) 2004-07-09
EP1575419A4 (en) 2009-11-11
WO2004054433A3 (en) 2005-09-09
EP1575419A2 (en) 2005-09-21
WO2004054433A2 (en) 2004-07-01
AU2010201151A1 (en) 2010-04-15
JP5305554B2 (ja) 2013-10-02
JP2006514643A (ja) 2006-05-11
CA2509817A1 (en) 2004-07-01
US20060252671A1 (en) 2006-11-09
AU2003295697A1 (en) 2004-07-09
US8075922B2 (en) 2011-12-13
JP2010120971A (ja) 2010-06-03
AU2010201151B2 (en) 2012-12-13
CA2509817C (en) 2014-11-04
EP1575419B1 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
AU2010201151B2 (en) Forming Iron Nitrosyl Hemoglobin
US7211560B2 (en) Reduced side-effect hemoglobin compositions
Alayash et al. Hemoglobin and free radicals: implications for the development of a safe blood substitute
Pittman Oxygen transport
NL8720283A (nl) Acellulair vervangingsmiddel voor rode bloedlichaampjes.
HU211989A9 (en) Low affinity mutant hemoglobins and wholly artificial hemoglobins as blood substitutes
EP0361719B1 (en) Haemoglobin based blood substitute and method for the preparation thereof
Cooper et al. Taming hemoglobin chemistry—a new hemoglobin-based oxygen carrier engineered with both decreased rates of nitric oxide scavenging and lipid oxidation
Conover et al. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models
Keipert et al. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute
ES2202535T3 (es) Hemoglobina provista de ligandos protectores de los sitios de union al oxigeno artificial para la aplicacion biologico-medica directa y procedimiento para su preparacion.
US6160098A (en) Method for control of functionality during cross-linking of hemoglobins
Malcolm et al. Diaspirin Cross-Linked Hemoglobin Solution as a Resuscitatwe Fluid Following Severe Hemorrhage in the Rat
EP1163010B1 (en) Hemoglobin-antioxidant conjugates
US7285379B2 (en) Artificial oxygen carrier and production method thereof
WO1999018979A1 (en) Storage-stable hemoglobin composition
JP2006514643A5 (cg-RX-API-DMAC7.html)
US6812207B1 (en) Hemoglobin mutants that reduce heme loss
WO1995007932A1 (en) Improvements in or relating to haemoglobin
Winslow Oxygen transport agents: a new approach to red blood cell alternatives
US20250064942A1 (en) Artificial oxygen carrier blood product
AU715073C (en) Hemoglobin mutants that reduce heme loss
WO1998003187A1 (en) Proendothelin and hemoglobin in the treatment of acute hemorrhage
US20250186381A1 (en) Artificial oxygen carrier blood product
Kuznetsova et al. The use of polycondensed hemoglobin as the basis of a blood substitute capable of transporting oxygen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired